PLx Pharma Inc. (PLXP) Financial Statements (2024 and earlier)
Company Profile
Business Address |
9 FISHERS LANE SPARTA, NJ 07871 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 35,730 | 52,499 | 82,554 | 80,169 | 84,423 | ||||
Cash and cash equivalents | 35,730 | 52,499 | 82,554 | 80,169 | 84,423 | ||||
Receivables | 490 | 698 | 3,253 | ||||||
Inventory, net of allowances, customer advances and progress billings | 3,883 | 3,839 | 2,190 | 1,262 | |||||
Inventory | 3,883 | 3,839 | 2,190 | 1,262 | |||||
Deferred costs | 3,883 | 3,839 | 2,190 | 1,262 | 143 | ||||
Other undisclosed current assets | (2,507) | (3,127) | (1,574) | (681) | 301 | ||||
Total current assets: | 41,479 | 57,748 | 88,614 | 82,013 | 84,867 | ||||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 204 | 255 | 299 | 250 | |||||
Property, plant and equipment | 798 | 828 | 889 | 919 | 1,126 | ||||
Intangible assets, net (including goodwill) | 2,061 | 2,061 | 2,061 | 2,061 | 2,061 | ||||
Goodwill | 2,061 | 2,061 | 2,061 | 2,061 | 2,061 | ||||
Deposits noncurrent assets | 17 | 17 | 17 | 17 | |||||
Other noncurrent assets | 202 | ||||||||
Total noncurrent assets: | 3,061 | 3,110 | 3,222 | 3,296 | 3,454 | ||||
TOTAL ASSETS: | 44,540 | 60,858 | 91,836 | 85,309 | 88,321 | ||||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 8,212 | 12,716 | 6,452 | 2,382 | 963 | ||||
Other undisclosed accounts payable and accrued liabilities | 8,212 | 12,716 | 6,452 | 2,382 | 963 | ||||
Other liabilities | 127 | 120 | 114 | 166 | 200 | ||||
Other undisclosed current liabilities | 729 | 394 | 840 | 516 | 247 | ||||
Total current liabilities: | 9,068 | 13,230 | 7,405 | 3,065 | 1,409 | ||||
Noncurrent Liabilities | |||||||||
Liabilities, other than long-term debt | 2,838 | 5,516 | 37,395 | 25,986 | 17,748 | ||||
Other liabilities | 79 | 106 | 165 | 194 | 122 | ||||
Derivative instruments and hedges, liabilities | 2,759 | 5,410 | 37,229 | 25,791 | 17,626 | ||||
Other undisclosed noncurrent liabilities | 129 | 129 | 129 | 129 | 3,118 | ||||
Total noncurrent liabilities: | 2,967 | 5,645 | 37,523 | 26,115 | 20,866 | ||||
Total liabilities: | 12,035 | 18,875 | 44,929 | 29,179 | 22,275 | ||||
Equity | |||||||||
Equity, attributable to parent | 16,491 | 25,969 | 30,894 | 40,116 | 44,661 | ||||
Common stock | 28 | 28 | 27 | 26 | 23 | ||||
Additional paid in capital | 187,380 | 185,000 | 182,702 | 170,283 | 158,327 | ||||
Accumulated deficit | (170,917) | (159,059) | (151,836) | (130,194) | (113,689) | ||||
Other undisclosed equity | 16,014 | 16,014 | 16,014 | 16,014 | 21,385 | ||||
Total equity: | 32,505 | 41,983 | 46,907 | 56,129 | 66,046 | ||||
TOTAL LIABILITIES AND EQUITY: | 44,540 | 60,858 | 91,836 | 85,309 | 88,321 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 483 | 2,083 | (6,616) | 6,616 | 63 | |||
Sublease income | 63 | |||||||
Cost of revenue | (820) | (1,169) | (3,913) | |||||
Cost of goods and services sold | (100) | |||||||
Gross profit: | (337) | 914 | 2,703 | 63 | ||||
Operating expenses | (14,201) | (19,110) | (12,565) | (6,480) | (3,596) | |||
Other undisclosed operating loss | (63) | |||||||
Operating loss: | (14,538) | (18,196) | (9,862) | (6,480) | (3,596) | |||
Nonoperating income (expense) | 2,680 | 7,411 | (11,781) | (10,024) | (7,945) | |||
Loss from continuing operations: | (11,858) | (10,785) | (21,642) | (16,504) | (11,541) | |||
Loss before gain (loss) on sale of properties: | (11,858) | (10,785) | ✕ | (21,642) | (16,504) | (11,541) | ||
Net loss attributable to parent: | (11,858) | (10,785) | (21,642) | (16,504) | (11,541) | |||
Preferred stock dividends and other adjustments | (2,203) | (322) | ||||||
Net loss available to common stockholders, diluted: | (11,858) | (10,785) | (21,642) | (18,707) | (11,863) |
Comprehensive Income ($ in thousands)Annual | Quarterly
9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (11,858) | (10,785) | (21,642) | (16,504) | (11,541) | |||
Comprehensive loss, net of tax, attributable to parent: | (11,858) | (10,785) | (21,642) | (16,504) | (11,541) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.